Trial Profile
Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Allogeneic bone marrow derived mesenchymal stromal cell therapy Orbsen Therapeutics (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; First in man
- Acronyms NEPHSTROM
- 13 Apr 2024 This trial has been completed in Ireland (End Date: 12 Sep 2023), according to European Clinical Trials Database record.
- 18 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Mar 2024.
- 26 Jan 2023 According to an Orbsen Therapeutics media release, consortium is preparing to submit these first-cohort interim results for publication in a peer-reviewed journal.